ReNerve Expands Clinical Trial for FDA-Cleared NervAlign Nerve Cuff Following Positive Interim Results
Key Insights
ReNerve Limited (search) has expanded its clinical study of the NervAlign Nerve Cuff (search), an FDA-cleared medical device designed to protect repaired peripheral nerves and improve surgical outcomes.
The expanded randomized controlled trial will enroll approximately 240 patients across multiple US centers, comparing standard care with and without the nerve cuff device.
Interim data presented in March 2025 demonstrated statistically significant reductions in pain scores for patients receiving the NervAlign Nerve Cuff (search) compared to standard care alone.
ReNerve Limited (search), an Australian medical device company specializing in peripheral nerve injury (search) solutions, has announced the expansion of its clinical study evaluating the NervAlign Nerve Cuff (search) following promising interim results. The FDA-cleared device is designed to provide a protective barrier around repaired nerves, potentially improving surgical outcomes and patient recovery for individuals with peripheral nerve injuries.
Study Design and Expansion
The expanded clinical trial builds upon statistically significant interim data presented in March 2025, with ReNerve now pursuing a definitive assessment of the Nerve Cuff's efficacy. The study employs a randomized controlled design comparing standard of care with and without the NervAlign Nerve Cuff (search) across multiple US centers.
The trial features two randomized parallel cohorts, each comprising approximately 120 patients. The control group receives standard care alone, while the intervention group receives standard care plus the NervAlign Nerve Cuff (search), bringing the total enrollment target to approximately 240 patients.
Primary and Secondary Endpoints
The study's primary endpoints focus on changes in pre and post-operative pain scores and functional recovery metrics. Secondary endpoints include comprehensive assessments of patient quality of life and surgical site outcomes, providing a holistic view of the device's impact on patient care.
Promising Interim Results
According to ReNerve CEO Dr Julian Chick, the expansion extends the study cohort from trial data presented earlier this year, which emphasized the benefit of using the nerve cuff to protect the nerve post-surgery. The previous interim data showed a significant reduction in pain scores for patients using the NervAlign Nerve Cuff (search) compared to standard care alone.
"The previous data showed a significant reduction in pain scores for patients using the NervAlign Nerve Cuff (search)," Dr Chick highlighted, underscoring the clinical potential of the device.
Dr David Rhodes, Chief Scientific Officer at ReNerve, expressed enthusiasm about advancing the clinical program, stating that the company is eager to further validate the potential of the NervAlign Nerve Cuff (search).
Study Progress and Timeline
The clinical study is currently being conducted across three centers in the United States, with ReNerve exploring the inclusion of additional sites to accelerate patient recruitment. Approximately one-third of the target enrollment has been achieved to date.
ReNerve anticipates completion of patient recruitment around midyear 2026, positioning the company to generate comprehensive efficacy and safety data for regulatory submissions. The study results will also support a European market approval filing for the NervAlign Nerve Cuff (search), potentially expanding the device's global reach.
Clinical Significance
The NervAlign Nerve Cuff (search) represents an innovative approach to peripheral nerve injury (search) management, addressing a significant clinical need in nerve repair surgery. The device's FDA clearance and the positive interim clinical data suggest potential for improved patient outcomes in this challenging therapeutic area.